Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23134818 | 1.00 | MAPK1 (0.35) | MAPK1HDAC6HDAC1HDAC2CA1 | |
| SCHEMBL1447140 | 0.86 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL13490197 | 0.86 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL9354885 | 0.83 | HDAC6 (0.33) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL21610053 | 0.82 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL22766361 | 0.82 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL20033588 | 0.82 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL21610067 | 0.82 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL1456149 | 0.82 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA1CA2 | |
| SCHEMBL24904226 | 0.82 | CA14 (0.32) | HDAC6HDAC1HDAC2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEONE MEDICINES I GMBH (CH) | 2026-04-28 | — | — | US | disclosed |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-05 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2025-09-23 | — | — | US | disclosed |
| EP-4565584-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | Bayer Aktiengesellschaft (DE) | 2025-06-11 | — | — | EP | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | BEIGENE, LTD. (KY) | 2025-04-22 | — | — | US | disclosed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| EP-3921319-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| EP-3580224-B1 | ASK1 INHIBITING AGENTS | BIOGEN MA INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2022-04-21 | — | — | US | disclosed |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-04-14 | — | — | US | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
| EP-3908277-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | Zhang, Xiaohu (CN) | 2021-11-17 | — | — | EP | disclosed |
| WO-2021060351-A1 | NSAID-BONDED ALGINIC ACID DERIVATIVE | 持田製薬株式会社 | 2021-04-01 | — | — | WO | disclosed |
| WO-2020146858-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020146858-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE INC. (KY) | 2020-07-16 | — | — | WO | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | TNF, LITAF, PNLIP | MAPK1 3218/4885HDAC6 1051/4885HDAC1 1790/4885 |
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | MAPK1 4123/4885HDAC6 360/4885HDAC1 904/4885 |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | TNF, LITAF, PNLIP | MAPK1 3218/4885HDAC6 1051/4885HDAC1 1790/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | MAPK1 245/4885HDAC6 480/4885HDAC1 102/4885 |
| US-12612407-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR8, TLR1 | MAPK1 537/4885HDAC6 896/4885HDAC1 697/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | MAPK1 4455/4885HDAC6 422/4885HDAC1 956/4885 |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR3 | MAPK1 672/4885HDAC6 320/4885HDAC1 403/4885 |
| US-20260035365-A1 | 1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS IRREVERSIBLE INHIBITORS OF MUTANT EGFR FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | MAPK1 79/4885HDAC6 2204/4885HDAC1 2509/4885 |
| US-12281119-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as TLR7 agonist | TLR7, TLR1, TLR3 | MAPK1 672/4885HDAC6 320/4885HDAC1 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.